Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Baxter
Moodys
Johnson and Johnson
Merck
Chubb

Generated: June 27, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR XOFIGO

Try a free trialSee Plans and Pricing

« Back to Dashboard

Clinical Trials for XOFIGO

Trial ID Title Status Sponsor Phase Summary
NCT00667199 BAY88-8223, Does Response Study in HRPC Patients Completed Bayer Phase 2 The purpose of this study is to evaluate the efficacy and safety of the investigational radioisotope Radium-223, Xofigo (Alpharadin), in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
NCT00667537 PK in Pts With HRPC & Skeletal Metastes Completed Bayer Phase 1 Primary objective: To investigate the biodistribution, radiation dosimetry, and pharmacokinetics of two separate intravenous (IV) injections of Xofigo (100 kBq/kg body weight [b.w.] [=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization], 6 weeks apart). Secondary objectives: To determine the safety of IV injections of Xofigo after two separate injections (6 weeks apart), to evaluate treatment response (antitumour effect in osteoblastic bone metastases) of Xofigo treatment consisting of two injections of activity 100 kBq/kg b.w. (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization), 6 weeks apart and to evaluate long term radiation toxicity and to collect survival data at 6 and 12 months after the first injection
NCT00748046 Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton Completed Bayer Phase 1 The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for XOFIGO

Condition Name

Condition Name for XOFIGO
Intervention Trials
Prostate Cancer 4
Prostatic Neoplasms, Castration-Resistant 3
Bone Metastases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for XOFIGO
Intervention Trials
Prostatic Neoplasms 15
Neoplasm Metastasis 8
Bone Neoplasms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for XOFIGO

Trials by Country

Trials by Country for XOFIGO
Location Trials
United States 9
Germany 2
United Kingdom 2
Spain 1
Norway 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for XOFIGO
Location Trials
California 3
Texas 2
Massachusetts 1
Pennsylvania 1
New Jersey 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for XOFIGO

Clinical Trial Phase

Clinical Trial Phase for XOFIGO
Clinical Trial Phase Trials
Phase 3 1
Phase 2 8
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for XOFIGO
Clinical Trial Phase Trials
Recruiting 7
Not yet recruiting 6
Completed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for XOFIGO

Sponsor Name

Sponsor Name for XOFIGO
Sponsor Trials
Bayer 12
M.D. Anderson Cancer Center 2
National Cancer Institute (NCI) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for XOFIGO
Sponsor Trials
Industry 14
Other 11
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
US Department of Justice
McKinsey
Express Scripts
Deloitte
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.